Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma

Abstract

Primary hepatic carcinoma is 1 of the most common malignant tumors globally, of which hepatocellular carcinoma (HCC) accounts for 85% to 90%. Due to the high degree of deterioration and low early detection rate of HCC, most patients are diagnosed when they are already in the middle and advanced stages, and the prognosis are always poor. RNA sequencing data from the cancer genome atlas was used to explore differences in lncRNA expression profiles. LncRNA was extracted by gdcRNAtools in R package. Multivariate cox analysis was performed on the screened lncRNAs. The relationship between the lncRNA model and prognosis as well as clinical characteristics of patients with HCC was analyzed. Finally, a predictive nomogram in the the cancer genome atlas cohort was established and verified internally Based on the RNA sequencing survival analysis, a 9- lncRNAs prognosis model, including TMCC1-AS1, AC008892.1, AL031985.3, L34079.2, U95743.1, KDM4A-AS1, SACS-AS1, AC005534.1, LINC01116 was established. The 9-lncRNA prognosis model was a reliable tool for predicting prognosis of HCC, and the nomogram of this prognosis model could help clinicians to choose personalized treatment for HCC patients This model was significant to complement clinic characteristics of HCC and to promote personalized management of patients, it also provided a new idea for researches on the prognosis of HCC.

Identification of a Five-Autophagy-Related-lncRNA Signature as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

“…Our five AR lncRNAs include TMCC1-AS1, PLBD1-AS1, MKLN1-AS, LINC01063, and CYTOR, all of which were highly expressed in the high-risk group with poor OS. Consistent with our findings, previous studies have shown that HCC patients with higher expression of TMCC1-AS1 showed shorter OS when compared with the low-expression ones (Zhao et al, 2018 ; Deng et al, 2020 ). CYTOR has been reported as an adverse factor of pan cancers via promoting proliferation, migration, invasion, metastasis, and drug resistance of tumor cells (Wang et al, 2018 ; Zhang and Li, 2018 ; Liu et al, 2019a ; Zou et al, 2019 ; Chen W. et al, 2020 ; Zhu et al, 2020a ).…”

Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma

“…Deng et al 26 analyzed the expression levels of nine lncRNAs to set up a signature for predicting the survival of patients with HCC. Generally, lncRNAs with high abundance possess significant biological function.…”

Image_1.TIF

“…Our five AR lncRNAs include TMCC1-AS1, PLBD1-AS1, MKLN1-AS, LINC01063, and CYTOR, all of which were highly expressed in the high-risk group with poor OS. Consistent with our findings, previous studies have shown that HCC patients with higher expression of TMCC1-AS1 showed shorter OS when compared with the low-expression ones (Zhao et al, 2018;Deng et al, 2020). CYTOR has been reported as an adverse factor of pan cancers via promoting proliferation, migration, invasion, metastasis, and drug resistance of tumor cells (Wang et al, 2018;Zhang and Li, 2018;Liu et al, 2019a;Zou et al, 2019;Zhu et al, 2020a).…”